ID   ZN363_HUMAN             Reviewed;         261 AA.
AC   Q96PM5; B3KRG3; C7E541; C7E542; C7E543; D3YRV2; E7EMC8; E7ETW5;
AC   J3KPI0; Q2KN33; Q59GN7; Q86X26; Q96PR5;
DT   28-FEB-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   10-MAY-2017, entry version 149.
DE   RecName: Full=RING finger and CHY zinc finger domain-containing protein 1;
DE            EC=2.3.2.27;
DE   AltName: Full=Androgen receptor N-terminal-interacting protein;
DE   AltName: Full=CH-rich-interacting match with PLAG1;
DE   AltName: Full=E3 ubiquitin-protein ligase Pirh2;
DE   AltName: Full=RING finger protein 199;
DE   AltName: Full=RING-type E3 ubiquitin transferase RCHY1;
DE   AltName: Full=Zinc finger protein 363;
DE   AltName: Full=p53-induced RING-H2 protein;
DE            Short=hPirh2;
GN   Name=RCHY1; Synonyms=ARNIP, CHIMP, PIRH2, RNF199, ZNF363;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), FUNCTION, SUBUNIT,
RP   INTERACTION WITH TP53 AND MDM2, UBIQUITINATION, SUBCELLULAR LOCATION,
RP   AND ALTERNATIVE SPLICING.
RX   PubMed=19483087; DOI=10.1074/jbc.M109.024232;
RA   Corcoran C.A., Montalbano J., Sun H., He Q., Huang Y., Sheikh M.S.;
RT   "Identification and characterization of two novel isoforms of Pirh2
RT   ubiquitin ligase that negatively regulate p53 independent of RING
RT   finger domains.";
RL   J. Biol. Chem. 284:21955-21970(2009).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Beitel L.K., Lumbroso R., Panet-Raymond V., de Tourreil A.S.,
RA   Pinsky L., Trifiro M.A.;
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Braem C.V., Kas K.;
RT   "Identification of PLAG1 interacting proteins.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Wu H.-S., Chou C.-M., Leu J.-H., Huang C.-J.;
RT   "A novel human zinc-finger protein.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RX   PubMed=20452352; DOI=10.1016/j.febslet.2010.04.075;
RA   Wu G., Sun M., Zhang L., Zhou J., Wang Y., Huo K.;
RT   "A novel hPirh2 splicing variant without ubiquitin protein ligase
RT   activity interacts with p53 and is down-regulated in hepatocellular
RT   carcinoma.";
RL   FEBS Lett. 584:2772-2778(2010).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND ALTERNATIVE SPLICING.
RX   PubMed=20357911; DOI=10.4255/mcpharmacol.10.04;
RA   Shi J., Huang Y., Sheikh M.S.;
RT   "Identification of Pirh2D, an additional novel isoform of Pirh2
RT   ubiquitin ligase.";
RL   Mol. Cell. Pharmacol. 2:21-23(2010).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   UBIQUITINATION, INTERACTION WITH KAT5, AND SUBCELLULAR LOCATION.
RX   PubMed=14701804; DOI=10.1074/jbc.M312712200;
RA   Logan I.R., Sapountzi V., Gaughan L., Neal D.E., Robson C.N.;
RT   "Control of human PIRH2 protein stability: involvement of TIP60 and
RT   the proteosome.";
RL   J. Biol. Chem. 279:11696-11704(2004).
RN   [13]
RP   INTERACTION WITH GORAB, AND SUBCELLULAR LOCATION.
RX   PubMed=15781263; DOI=10.1016/j.bbrc.2005.02.156;
RA   Zhang L., Li J., Wang C., Ma Y., Huo K.;
RT   "A new human gene hNTKL-BP1 interacts with hPirh2.";
RL   Biochem. Biophys. Res. Commun. 330:293-297(2005).
RN   [14]
RP   FUNCTION, INTERACTION WITH AR; KAT5 AND HDAC1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16914734; DOI=10.1128/MCB.00147-06;
RA   Logan I.R., Gaughan L., McCracken S.R.C., Sapountzi V., Leung H.Y.,
RA   Robson C.N.;
RT   "Human PIRH2 enhances androgen receptor signaling through inhibition
RT   of histone deacetylase 1 and is overexpressed in prostate cancer.";
RL   Mol. Cell. Biol. 26:6502-6510(2006).
RN   [15]
RP   SUBUNIT, INTERACTION WITH PLAGL2, AND PROTEASOMAL DEGRADATION.
RX   PubMed=17950244; DOI=10.1016/j.bbrc.2007.10.003;
RA   Zheng G., Ning J., Yang Y.-C.;
RT   "PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for
RT   p53.";
RL   Biochem. Biophys. Res. Commun. 364:344-350(2007).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CDKN1B.
RX   PubMed=18006823; DOI=10.1158/0008-5472.CAN-07-2033;
RA   Hattori T., Isobe T., Abe K., Kikuchi H., Kitagawa K., Oda T.,
RA   Uchida C., Kitagawa M.;
RT   "Pirh2 promotes ubiquitin-dependent degradation of the cyclin-
RT   dependent kinase inhibitor p27Kip1.";
RL   Cancer Res. 67:10789-10795(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH COPE.
RX   PubMed=17721809; DOI=10.1007/s11010-007-9586-3;
RA   Maruyama S., Miyajima N., Bohgaki M., Tsukiyama T., Shigemura M.,
RA   Nonomura K., Hatakeyama S.;
RT   "Ubiquitylation of epsilon-COP by PIRH2 and regulation of the
RT   secretion of PSA.";
RL   Mol. Cell. Biochem. 307:73-82(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   FUNCTION.
RX   PubMed=21994467; DOI=10.1158/1541-7786.MCR-11-0157;
RA   Wu H., Zeinab R.A., Flores E.R., Leng R.P.;
RT   "Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity
RT   by promoting its ubiquitination.";
RL   Mol. Cancer Res. 9:1780-1790(2011).
RN   [21]
RP   FUNCTION.
RX   PubMed=21791603; DOI=10.1128/MCB.05808-11;
RA   Jung Y.S., Hakem A., Hakem R., Chen X.;
RT   "Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to
RT   suppress translesion DNA synthesis.";
RL   Mol. Cell. Biol. 31:3997-4006(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   STRUCTURE BY NMR OF 138-189 IN COMPLEX WITH ZINC IONS, FUNCTION,
RP   MUTAGENESIS OF MET-176 AND CYS-186, AND INTERACTION WITH TP53 AND
RP   UBE2D2.
RX   PubMed=19043414; DOI=10.1038/nsmb.1521;
RA   Sheng Y., Laister R.C., Lemak A., Wu B., Tai E., Duan S., Lukin J.,
RA   Sunnerhagen M., Srisailam S., Karra M., Benchimol S., Arrowsmith C.H.;
RT   "Molecular basis of Pirh2-mediated p53 ubiquitylation.";
RL   Nat. Struct. Mol. Biol. 15:1334-1342(2008).
CC   -!- FUNCTION: Mediates E3-dependent ubiquitination and proteasomal
CC       degradation of target proteins, including p53/TP53, P73, HDAC1 and
CC       CDKN1B. Preferentially acts on tetrameric p53/TP53.
CC       Monoubiquitinates the translesion DNA polymerase POLH. Contributes
CC       to the regulation of the cell cycle progression. Increases AR
CC       transcription factor activity. {ECO:0000269|PubMed:16914734,
CC       ECO:0000269|PubMed:17721809, ECO:0000269|PubMed:18006823,
CC       ECO:0000269|PubMed:19043414, ECO:0000269|PubMed:19483087,
CC       ECO:0000269|PubMed:21791603, ECO:0000269|PubMed:21994467}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Monomer and homodimer. Interacts with AR, p53/TP53, MDM2,
CC       HDAC1, KAT5, PLAG1, PLAGL2, CDKN1B, COPE, UBE2D2 and
CC       GORAB/NTKLBP1. {ECO:0000269|PubMed:14701804,
CC       ECO:0000269|PubMed:15781263, ECO:0000269|PubMed:16914734,
CC       ECO:0000269|PubMed:17721809, ECO:0000269|PubMed:17950244,
CC       ECO:0000269|PubMed:18006823, ECO:0000269|PubMed:19043414,
CC       ECO:0000269|PubMed:19483087}.
CC   -!- INTERACTION:
CC       Q6UY14-3:ADAMTSL4; NbExp=3; IntAct=EBI-947779, EBI-10173507;
CC       Q9NVV5:AIG1; NbExp=4; IntAct=EBI-947779, EBI-3942989;
CC       Q6UXH0:ANGPTL8; NbExp=2; IntAct=EBI-947779, EBI-3943039;
CC       P18085:ARF4; NbExp=3; IntAct=EBI-947779, EBI-1237085;
CC       P62158:CALM3; NbExp=2; IntAct=EBI-947779, EBI-397435;
CC       P04196:HRG; NbExp=3; IntAct=EBI-947779, EBI-3915012;
CC       O60662:KLHL41; NbExp=3; IntAct=EBI-947779, EBI-5353084;
CC       Q9BYQ4:KRTAP9-2; NbExp=3; IntAct=EBI-947779, EBI-1044640;
CC       Q7Z4I7-5:LIMS2; NbExp=3; IntAct=EBI-947779, EBI-10257651;
CC       A4D127:MEOX2; NbExp=3; IntAct=EBI-947779, EBI-10172134;
CC       Q969F2:NKD2; NbExp=2; IntAct=EBI-947779, EBI-1538629;
CC       Q9UBE8:NLK; NbExp=5; IntAct=EBI-947779, EBI-366978;
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-947779, EBI-945833;
CC       Q9C0C4:SEMA4C; NbExp=3; IntAct=EBI-947779, EBI-10303490;
CC       P04637:TP53; NbExp=7; IntAct=EBI-947779, EBI-366083;
CC       Q8TF42:UBASH3B; NbExp=5; IntAct=EBI-947779, EBI-1380492;
CC       Q6RFH5:WDR74; NbExp=3; IntAct=EBI-947779, EBI-722366;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Nucleus speckle. Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=1; Synonyms=A;
CC         IsoId=Q96PM5-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=Q96PM5-2; Sequence=VSP_038467;
CC       Name=3; Synonyms=C;
CC         IsoId=Q96PM5-3; Sequence=VSP_038468;
CC       Name=4; Synonyms=Pirh2b;
CC         IsoId=Q96PM5-4; Sequence=VSP_044085;
CC         Note=No ubiquitin protein ligase activity. Down-regulated in
CC         hepatocellular carcinoma.;
CC       Name=5; Synonyms=Pirh2D;
CC         IsoId=Q96PM5-5; Sequence=VSP_053385, VSP_053386;
CC       Name=6;
CC         IsoId=Q96PM5-6; Sequence=VSP_053787;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data.;
CC       Name=7;
CC         IsoId=Q96PM5-7; Sequence=VSP_053788;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on partial mRNA data.;
CC       Name=8;
CC         IsoId=Q96PM5-8; Sequence=VSP_053788, VSP_038467;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data.;
CC   -!- INDUCTION: Up-regulated during the S phase of the cell cycle.
CC       Expressed at low levels during G phase.
CC   -!- PTM: Subject to ubiquitination and proteasomal degradation.
CC       Interaction with PLAGL2 or KAT5 enhances protein stability.
CC       {ECO:0000269|PubMed:14701804, ECO:0000269|PubMed:19483087}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92309.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RCHY1ID43012ch04q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; GQ250944; ACT35531.1; -; mRNA.
DR   EMBL; GQ250945; ACT35532.1; -; mRNA.
DR   EMBL; GQ250946; ACT35533.1; -; mRNA.
DR   EMBL; AF247041; AAL76101.1; -; mRNA.
DR   EMBL; AF255666; AAK96896.1; -; mRNA.
DR   EMBL; AF305424; AAL09356.1; -; mRNA.
DR   EMBL; AB209072; BAD92309.1; ALT_INIT; mRNA.
DR   EMBL; AY888047; AAX78233.1; -; mRNA.
DR   EMBL; GU937000; ADD21555.1; -; mRNA.
DR   EMBL; AK091501; BAG52375.1; -; mRNA.
DR   EMBL; AC096759; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471057; EAX05725.1; -; Genomic_DNA.
DR   EMBL; BC047393; AAH47393.1; -; mRNA.
DR   CCDS; CCDS34012.1; -. [Q96PM5-2]
DR   CCDS; CCDS3567.1; -. [Q96PM5-1]
DR   CCDS; CCDS63990.1; -. [Q96PM5-8]
DR   CCDS; CCDS63991.1; -. [Q96PM5-7]
DR   CCDS; CCDS63992.1; -. [Q96PM5-6]
DR   RefSeq; NP_001009922.1; NM_001009922.2. [Q96PM5-2]
DR   RefSeq; NP_001265465.1; NM_001278536.1. [Q96PM5-7]
DR   RefSeq; NP_001265466.1; NM_001278537.1. [Q96PM5-8]
DR   RefSeq; NP_001265467.1; NM_001278538.1. [Q96PM5-6]
DR   RefSeq; NP_056251.2; NM_015436.3. [Q96PM5-1]
DR   UniGene; Hs.48297; -.
DR   PDB; 2JRJ; NMR; -; A=143-189.
DR   PDB; 2K2C; NMR; -; A=1-137.
DR   PDB; 2K2D; NMR; -; A=187-261.
DR   PDBsum; 2JRJ; -.
DR   PDBsum; 2K2C; -.
DR   PDBsum; 2K2D; -.
DR   ProteinModelPortal; Q96PM5; -.
DR   SMR; Q96PM5; -.
DR   BioGrid; 117406; 82.
DR   DIP; DIP-43981N; -.
DR   IntAct; Q96PM5; 49.
DR   MINT; MINT-3057007; -.
DR   STRING; 9606.ENSP00000321239; -.
DR   iPTMnet; Q96PM5; -.
DR   PhosphoSitePlus; Q96PM5; -.
DR   BioMuta; RCHY1; -.
DR   DMDM; 32700008; -.
DR   REPRODUCTION-2DPAGE; Q96PM5; -.
DR   EPD; Q96PM5; -.
DR   MaxQB; Q96PM5; -.
DR   PaxDb; Q96PM5; -.
DR   PeptideAtlas; Q96PM5; -.
DR   PRIDE; Q96PM5; -.
DR   DNASU; 25898; -.
DR   Ensembl; ENST00000324439; ENSP00000321239; ENSG00000163743. [Q96PM5-1]
DR   Ensembl; ENST00000380840; ENSP00000370220; ENSG00000163743. [Q96PM5-7]
DR   Ensembl; ENST00000505105; ENSP00000424631; ENSG00000163743. [Q96PM5-4]
DR   Ensembl; ENST00000507014; ENSP00000424472; ENSG00000163743. [Q96PM5-8]
DR   Ensembl; ENST00000512706; ENSP00000423976; ENSG00000163743. [Q96PM5-6]
DR   Ensembl; ENST00000513257; ENSP00000421084; ENSG00000163743. [Q96PM5-2]
DR   GeneID; 25898; -.
DR   KEGG; hsa:25898; -.
DR   UCSC; uc003hik.4; human. [Q96PM5-1]
DR   CTD; 25898; -.
DR   DisGeNET; 25898; -.
DR   GeneCards; RCHY1; -.
DR   HGNC; HGNC:17479; RCHY1.
DR   HPA; HPA030339; -.
DR   MIM; 607680; gene.
DR   neXtProt; NX_Q96PM5; -.
DR   OpenTargets; ENSG00000163743; -.
DR   PharmGKB; PA38240; -.
DR   eggNOG; KOG1940; Eukaryota.
DR   eggNOG; ENOG410XXHF; LUCA.
DR   GeneTree; ENSGT00390000008853; -.
DR   HOGENOM; HOG000231827; -.
DR   HOVERGEN; HBG062959; -.
DR   InParanoid; Q96PM5; -.
DR   KO; K10144; -.
DR   OMA; CGSYNTA; -.
DR   OrthoDB; EOG091G094U; -.
DR   PhylomeDB; Q96PM5; -.
DR   TreeFam; TF323762; -.
DR   BRENDA; 2.3.2.B10; 2681.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-110320; Translesion Synthesis by POLH.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SIGNOR; Q96PM5; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; RCHY1; human.
DR   EvolutionaryTrace; Q96PM5; -.
DR   GeneWiki; RCHY1; -.
DR   GenomeRNAi; 25898; -.
DR   PRO; PR:Q96PM5; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000163743; -.
DR   CleanEx; HS_RCHY1; -.
DR   ExpressionAtlas; Q96PM5; baseline and differential.
DR   Genevisible; Q96PM5; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HGNC.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IEA:Ensembl.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0070987; P:error-free translesion synthesis; TAS:Reactome.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR008913; Znf_CHY.
DR   InterPro; IPR017921; Znf_CTCHY.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF05495; zf-CHY; 1.
DR   Pfam; PF13639; zf-RING_2; 1.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS51266; ZF_CHY; 1.
DR   PROSITE; PS51270; ZF_CTCHY; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Transferase; Ubl conjugation; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    261       RING finger and CHY zinc finger domain-
FT                                containing protein 1.
FT                                /FTId=PRO_0000056312.
FT   ZN_FING      13     80       CHY-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00601}.
FT   ZN_FING      82    144       CTCHY-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00965}.
FT   ZN_FING     145    189       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   MOD_RES     257    257       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1     30       MAATAREDGASGQERGQRGCEHYDRGCLLK -> MAPAVKS
FT                                E (in isoform 6). {ECO:0000305}.
FT                                /FTId=VSP_053787.
FT   VAR_SEQ      31     70       Missing (in isoform 7 and isoform 8).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_053788.
FT   VAR_SEQ      68     75       IQHAQQTC -> NSTCPTDL (in isoform 5).
FT                                {ECO:0000303|PubMed:20357911}.
FT                                /FTId=VSP_053385.
FT   VAR_SEQ      76    261       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:20357911}.
FT                                /FTId=VSP_053386.
FT   VAR_SEQ     171    179       Missing (in isoform 2 and isoform 8).
FT                                {ECO:0000303|PubMed:19483087}.
FT                                /FTId=VSP_038467.
FT   VAR_SEQ     180    261       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:19483087}.
FT                                /FTId=VSP_038468.
FT   VAR_SEQ     180    261       GYRCPLCMHSALDMTRYWRQLDDEVAQTPMPSEYQNMTVDI
FT                                LCNDCNGRSTVQFHILGMKCKICESYNTAQAGGRRISLDQQ
FT                                -> YDQVLETAG (in isoform 4).
FT                                {ECO:0000303|PubMed:20452352}.
FT                                /FTId=VSP_044085.
FT   MUTAGEN     176    176       M->E: Abolishes E3 ubiquitin-protein
FT                                ligase activity.
FT                                {ECO:0000269|PubMed:19043414}.
FT   MUTAGEN     186    186       C->A: Abolishes E3 ubiquitin-protein
FT                                ligase activity.
FT                                {ECO:0000269|PubMed:19043414}.
FT   CONFLICT     11     13       SGQ -> TGE (in Ref. 1; ACT35531/ACT35532/
FT                                ACT35533 and 3; AAK96896). {ECO:0000305}.
FT   CONFLICT    142    142       R -> Q (in Ref. 11; AAH47393).
FT                                {ECO:0000305}.
FT   CONFLICT    220    220       I -> F (in Ref. 8; BAD92309).
FT                                {ECO:0000305}.
FT   STRAND       26     30       {ECO:0000244|PDB:2K2C}.
FT   TURN         32     34       {ECO:0000244|PDB:2K2C}.
FT   STRAND       37     40       {ECO:0000244|PDB:2K2C}.
FT   HELIX        41     47       {ECO:0000244|PDB:2K2C}.
FT   STRAND       48     50       {ECO:0000244|PDB:2K2C}.
FT   TURN         54     56       {ECO:0000244|PDB:2K2C}.
FT   STRAND       59     62       {ECO:0000244|PDB:2K2C}.
FT   TURN         63     65       {ECO:0000244|PDB:2K2C}.
FT   STRAND       68     71       {ECO:0000244|PDB:2K2C}.
FT   TURN         76     78       {ECO:0000244|PDB:2K2C}.
FT   STRAND       84     87       {ECO:0000244|PDB:2K2C}.
FT   TURN         88     91       {ECO:0000244|PDB:2K2C}.
FT   STRAND       92     94       {ECO:0000244|PDB:2K2C}.
FT   STRAND      100    102       {ECO:0000244|PDB:2K2C}.
FT   TURN        103    106       {ECO:0000244|PDB:2K2C}.
FT   STRAND      107    110       {ECO:0000244|PDB:2K2C}.
FT   TURN        113    115       {ECO:0000244|PDB:2K2C}.
FT   STRAND      116    119       {ECO:0000244|PDB:2K2C}.
FT   TURN        120    123       {ECO:0000244|PDB:2K2C}.
FT   STRAND      124    127       {ECO:0000244|PDB:2K2C}.
FT   TURN        128    132       {ECO:0000244|PDB:2K2C}.
FT   TURN        146    149       {ECO:0000244|PDB:2JRJ}.
FT   TURN        156    158       {ECO:0000244|PDB:2JRJ}.
FT   STRAND      159    161       {ECO:0000244|PDB:2JRJ}.
FT   STRAND      167    169       {ECO:0000244|PDB:2JRJ}.
FT   HELIX       170    179       {ECO:0000244|PDB:2JRJ}.
FT   HELIX       184    187       {ECO:0000244|PDB:2JRJ}.
FT   STRAND      217    225       {ECO:0000244|PDB:2K2D}.
FT   STRAND      228    232       {ECO:0000244|PDB:2K2D}.
FT   TURN        241    243       {ECO:0000244|PDB:2K2D}.
FT   STRAND      248    251       {ECO:0000244|PDB:2K2D}.
SQ   SEQUENCE   261 AA;  30110 MW;  AC03786F6B42A03D CRC64;
     MAATAREDGA SGQERGQRGC EHYDRGCLLK APCCDKLYTC RLCHDNNEDH QLDRFKVKEV
     QCINCEKIQH AQQTCEECST LFGEYYCDIC HLFDKDKKQY HCENCGICRI GPKEDFFHCL
     KCNLCLAMNL QGRHKCIENV SRQNCPICLE DIHTSRVVAH VLPCGHLLHR TCYEEMLKEG
     YRCPLCMHSA LDMTRYWRQL DDEVAQTPMP SEYQNMTVDI LCNDCNGRST VQFHILGMKC
     KICESYNTAQ AGGRRISLDQ Q
//
